Company profile: Echosens
1.1 - Company Overview
Company description
- Provider of non-invasive hepatology diagnostics, offering FibroScan devices for assessment of liver fibrosis and steatosis, including Next-Generation FibroScan, FibroScan 630 Expert for liver/spleen stiffness and ultrasound attenuation, and portable FibroScan Compact 530. Solutions include LSM by VCTE for fibrosis and CAP for steatosis, supported by extensive peer-reviewed publications and international guidelines.
Products and services
- FibroScan® 630 Expert: A performance-tuned device measuring liver and spleen stiffness and liver ultrasound attenuation, featuring high-speed processing and ergonomic design for precise hepatology assessments
- FibroScan®: A clinical-grade non-invasive device for assessing liver fibrosis and steatosis, globally recognized with extensive peer-reviewed publications and international guidelines supporting standardized hepatology use
- LSM by VCTE™: A standardized parameter for liver fibrosis assessment using vibration-controlled transient elastography, enabling quantitative stiffness metrics for disease staging in hepatology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Echosens
Cinclus Pharma
HQ: Sweden
Website
- Description: Provider of research-based biotech solutions developing small-molecule therapies for gastric acid–related diseases, notably linaprazan glurate for GERD and Helicobacter pylori with improved action over PPIs. Completed Phase II and preparing Phase III for GERD; QIDP designation from the FDA for H. pylori. Based in Basel, Switzerland; main asset X842 studied in Phase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cinclus Pharma company profile →
C2 Therapeutics
HQ: United States
Website
- Description: Provider of ablation therapies to treat diseases of the gastrointestinal tract.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C2 Therapeutics company profile →
Bausch Health
HQ: Canada
Website
- Description: Provider of specialty pharmaceuticals and aesthetic medical devices, developing and marketing treatments across gastrointestinal and hepatologic, dermatology (acne, psoriasis, actinic keratosis, atopic dermatitis), neurology, infectious diseases, oral health (adult periodontitis, mouth dryness), and generics. Divisions include Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical, International Pharmaceuticals (500+ products), and OraPharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bausch Health company profile →
Corpak MedSystems
HQ: United States
Website
- Description: Provider of enteral feeding and bedside location medical devices, developing, manufacturing, and marketing premium-branded solutions. Portfolio includes the CORTRAK* 2 Enteral Access System for real-time feeding tube placement; MIC-KEY* low-profile G, GJ, and J feeding tubes; the MIC-KEY* Over-the-Wire stoma measuring device; and MIC* PEG kits. Holds a leading position in adult long-term nasogastric feeding tubes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corpak MedSystems company profile →
9 Meters Biopharma
HQ: United States
Website
- Description: Provider of a gastrointestinal platform focused on patients with rare disorders and unmet needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 9 Meters Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Echosens
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Echosens
2.2 - Growth funds investing in similar companies to Echosens
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Echosens
4.2 - Public trading comparable groups for Echosens
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →